Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Plaque Psoriasis
NCT02592018Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Oct 2016
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of secukinumab in plaque psoriasis, sponsored by University of California, San Francisco. Primary endpoint: Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline at 12 weeks. Started Oct 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02592018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592018.